Insider · CIK 0001712069

Lang Matthew

Reports to the SEC for 4 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001712069

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-04-15	GPCRStructure Therapeutics Inc. · Share option (right to buy)A Award	COO & GC	AAward	+224K sh	—	—	223,776
2026-04-15	GPCRStructure Therapeutics Inc.A Award	COO & GC	AAward	+185K sh	—	—	184,614
2025-11-13	MTSRMetsera, Inc.D Disposition to Issuer	CHIEF LEGAL OFFICER	DDisposition to Issuer	−12.5K sh	—	—	0
2025-11-13	MTSRMetsera, Inc. · Restricted Stock UnitA Award	CHIEF LEGAL OFFICER	AAward	+12.5K sh	—	—	12,500
2025-11-13	MTSRMetsera, Inc. · Stock Option (right to buy)D Disposition to Issuer	CHIEF LEGAL OFFICER	DDisposition to Issuer	−46.9K sh	—	—	0
2025-11-13	MTSRMetsera, Inc. · Stock Option (right to buy)D Disposition to Issuer	CHIEF LEGAL OFFICER	DDisposition to Issuer	−325K sh	—	—	0
2025-05-20	MTSRMetsera, Inc. · Stock Option (Right to Buy)A Award	CHIEF LEGAL OFFICER	AAward	+46.9K sh	—	—	46,875
2025-02-10	LYELLyell Immunopharma, Inc.A Award	Chief Business Officer	AAward	+113K sh	—	—	162,500
2025-02-10	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Chief Business Officer	AAward	+56.3K sh	—	—	56,250
2025-02-10	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Chief Business Officer	AAward	+450K sh	—	—	450,000
2024-02-09	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Chief Business Officer	AAward	+500K sh	—	—	500,000
2024-02-09	LYELLyell Immunopharma, Inc.A Award	Chief Business Officer	AAward	+50K sh	—	—	50,000
2023-08-10	LYELLyell Immunopharma, Inc. · Option (right to buy)A Award	Chief Business Officer	AAward	+2.25M sh	—	—	2,250,000
2023-03-10	Myovant Sciences Ltd.Stock Options (Right to Buy)D Disposition to Issuer	General Counsel & Corp. Secy.	DDisposition to Issuer	−152K sh	—	—	0
2023-03-10	Myovant Sciences Ltd.Stock Options (Right to Buy)D Disposition to Issuer	General Counsel & Corp. Secy.	DDisposition to Issuer	−170K sh	—	—	0
2023-03-10	Myovant Sciences Ltd.Stock Options (Right to Buy)D Disposition to Issuer	General Counsel & Corp. Secy.	DDisposition to Issuer	−90.3K sh	—	—	0
2023-03-10	Myovant Sciences Ltd.Performance Stock UnitD Disposition to Issuer	General Counsel & Corp. Secy.	DDisposition to Issuer	−111K sh	—	—	0
2023-03-10	Myovant Sciences Ltd.Stock Options (Right to Buy)D Disposition to Issuer	General Counsel & Corp. Secy.	DDisposition to Issuer	−87.1K sh	—	—	0
2023-03-10	Myovant Sciences Ltd.Stock Options (Right to Buy)D Disposition to Issuer	General Counsel & Corp. Secy.	DDisposition to Issuer	−220K sh	—	—	0
2023-03-10	Myovant Sciences Ltd.D Disposition to Issuer	General Counsel & Corp. Secy.	DDisposition to Issuer	−241K sh	—	—	0
2023-03-10	Myovant Sciences Ltd.D Disposition to Issuer	General Counsel & Corp. Secy.	DDisposition to Issuer	−113K sh	—	—	241,158
2023-01-18	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−1,272 sh	$26.89	−$34.2K	354,303
2023-01-04	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−2,779 sh	$26.90	−$74.8K	355,575
2022-10-18	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−1,933 sh	$25.20	−$48.7K	358,354
2022-10-04	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−3,679 sh	$24.40	−$89.8K	360,287
2022-08-15	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−31.2K sh	$18.23	−$569K	363,966
2022-08-12	Myovant Sciences Ltd.A Award	General Counsel & Corp. Secy.	AAward	+125K sh	—	—	395,180
2022-07-18	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−1,935 sh	$12.87	−$24.9K	270,400
2022-07-06	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−3,702 sh	$13.40	−$49.6K	272,335
2022-04-19	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−8,002 sh	$10.45	−$83.6K	276,037
2022-04-15	Myovant Sciences Ltd.A Award	General Counsel & Corp. Secy.	AAward	+111K sh	—	—	284,039
2022-04-05	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−2,436 sh	$13.78	−$33.6K	172,928
2022-01-04	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−4,475 sh	$16.27	−$72.8K	175,364
2021-10-05	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−6,671 sh	$21.62	−$144K	179,839
2021-07-09	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−6,954 sh	$21.52	−$150K	186,510
2021-04-15	Myovant Sciences Ltd.A Award	General Counsel & Corp. Secy.	AAward	+58.5K sh	—	—	193,464
2021-04-15	Myovant Sciences Ltd.Stock Option (Right to Buy)A Award	General Counsel & Corp. Secy.	AAward	+90.3K sh	—	—	90,310
2021-04-06	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−10.9K sh	$18.62	−$202K	135,003
2021-03-15	Myovant Sciences Ltd.M Exercise/Conversion	General Counsel & Corp. Secy.	MExercise/Conversion	+30K sh	$7.78	+$233K	175,865
2021-03-15	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	General Counsel & Corp. Secy.	MExercise/Conversion	−30K sh	—	—	220,000
2021-03-15	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−30K sh	$25.07	−$752K	145,865
2020-12-18	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	General Counsel & Corp. Secy.	MExercise/Conversion	−10K sh	—	—	250,000
2020-12-18	Myovant Sciences Ltd.M Exercise/Conversion	General Counsel & Corp. Secy.	MExercise/Conversion	+10K sh	$7.78	+$77.8K	155,865
2020-12-18	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−9,700 sh	$25.38	−$246K	146,165
2020-12-18	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−300 sh	$26.24	−$7,871.01	145,865
2020-12-10	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	General Counsel & Corp. Secy.	MExercise/Conversion	−19.4K sh	—	—	260,000
2020-12-10	Myovant Sciences Ltd.M Exercise/Conversion	General Counsel & Corp. Secy.	MExercise/Conversion	+19.4K sh	$7.78	+$151K	165,265
2020-12-10	Myovant Sciences Ltd.S Sale	General Counsel & Corp. Secy.	SSale	−19.4K sh	$25.20	−$489K	145,865
2020-12-09	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	General Counsel & Corp. Secy.	MExercise/Conversion	−600 sh	—	—	279,400
2020-12-09	Myovant Sciences Ltd.M Exercise/Conversion	General Counsel & Corp. Secy.	MExercise/Conversion	+600 sh	$7.78	+$4,668	146,465

Recent filings

Accepted (ET)
Apr 234
Lang Matthew0001712069-26-000007
SEC(opens sec.gov)
Nov 134
Lang Matthew0001193125-25-280812
SEC(opens sec.gov)
May 224
Lang Matthew0000950170-25-076571
SEC(opens sec.gov)
Feb 264
Lang Matthew0001415889-25-005775
SEC(opens sec.gov)
Feb 134
Lang Matthew0001209191-24-003276
SEC(opens sec.gov)
Aug 114
Lang Matthew0001209191-23-045439
SEC(opens sec.gov)
Mar 104
Lang Matthew0001209191-23-017719
SEC(opens sec.gov)

Companies

Address

C/O STRUCTURE THERAPEUTICS INC. 601 GATEWAY BLVD., SUITE 900

SOUTH SAN FRANCISCO, CA, 94080